Published in Cancer Weekly, January 19th, 2010
Under the terms of the agreement, Debiopharm will assume responsibility for conducting the phase 3 trial of tremelimumab and Pfizer will retain responsibility for worldwide commercialization of the compound.
Melanoma, the deadliest form of skin cancer, occurs in about...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.